Generic entry timeline

ESMOLOL HYDROCHLORIDE generics — when can they launch?

ESMOLOL HYDROCHLORIDE (ESMOLOL HYDROCHLORIDE) · · 4 active US patents · 0 expired

Earliest patent expiry
2033-03-15
7 years remaining
Full patent estate to
2033-03-15
complete protection through 2033
FDA approval
1986

Where ESMOLOL HYDROCHLORIDE sits in the generic timeline

Long-dated protection: earliest active US patent for ESMOLOL HYDROCHLORIDE extends to 2033 (~7 years out). Generic competition is at least 4 years away. Lifecycle moves (new formulations, label extensions, combination filings) typically execute 18-36 months ahead of cliff.

Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.

Patent estate by type — active patents

Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.

  • Formulation — 4 patents

Sample patent estate

Showing 4 of 4 active US patents. View full estate on the ESMOLOL HYDROCHLORIDE drug page →

  • US8835505 Formulation · expires 2033-03-15
    This patent protects a ready-to-use injectable pharmaceutical composition containing Esmolol hydrochloride that can be stored in a modified flexible plastic container.
    USPTO title: Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container
  • US8829054 Formulation · expires 2033-03-15
    This patent protects a ready-to-use injectable pharmaceutical composition of Esmolol hydrochloride in a modified flexible plastic container that can be heat-sterilized.
    USPTO title: Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container
  • US8829054 Formulation · expires 2033-03-15
    This patent protects a ready-to-use injectable pharmaceutical composition of Esmolol hydrochloride in a modified flexible plastic container that can be heat-sterilized.
    USPTO title: Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container
  • US8835505 Formulation · expires 2033-03-15
    This patent protects a ready-to-use injectable pharmaceutical composition containing Esmolol hydrochloride that can be stored in a modified flexible plastic container.
    USPTO title: Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container

Sources

Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.

Get generic entry alerts

Free Pharma CI alerts on ESMOLOL HYDROCHLORIDE — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.

Subscribe free →